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Background: Autoimmune polyendocrine syndrome type 1, also known as autoimmune polyendocrinopathy-
candidiasis-ectodermal-dystrophy, is a rare autosomal recessive disease due to pathogenic variants in the AIRE
gene. Classic features of the syndrome are mucocutaneous candidiasis, chronic idiopathic hypoparathyroidism
and Addison disease. However, other endocrine and non-endocrine components, may occur with a different
prevalence. In addition to ectodermal features, which are quite common features of the disease, APS 1 patients
may experience other types of skin alterations, such as vasculitic skin rash. An early diagnosis of APS 1 can be very
challenging, due to the high clinical heterogeneity, and a considerable delay may occur between the appearance
of symptoms and the diagnosis.
Case presentation: We report on a girl affected by APS 1 who presented with cutaneous vasculitis when she was
seven-months old, some years before the onset of the common components of the disease.
Conclusion: Clinical picture of APS 1 may be characterized by isolated rare or atypical autoimmune or
immune-mediated manifestations, even years before the onset of the classic components of the disease. Among
these uncommon features, skin rashes of variable form and duration may occur, most of them being associated
with histopathological features of vasculitis. Our case suggests that cutaneous vasculitis may represent a first
sign of APS 1. The clinical significance of cutaneous vasculitis in the context of APS 1 is still debated. It may
represent a rare, unusual, early component of the disease or a clinical manifestation secondarily related to the typical
APS 1 components (i.e. autoimmune thyroid disease), which are frequently associated with rheumatologic-like signs
and symptoms. Alternatively, it may be the expression of an independent disease co-occuring with APS 1. In
conclusion, our case suggests that children presenting with unexplained vasculitic skin rash should be
followed-up in order to early identify APS 1.
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Autoimmune polyendocrine syndrome type 1 (APS 1), also
known as autoimmune polyendocrinopathy-candidiasis-
ectodermal dystrophy (APECED), is a rare autosomal
recessive disease caused by pathogenic variants in the
autoimmune regulator (AIRE) gene. AIRE encodes for the
homonymous protein, AIRE, which acts as a regulator of* Correspondence: salerno@unina.it
1Unit of Pediatric Endocrinology, Department of Traslational Medical
Sciences, “Federico II” University of Naples, Naples, Italy
Full list of author information is available at the end of the article
© 2014 Improda et al.; licensee BioMed Centra
Commons Attribution License (http://creativec
reproduction in any medium, provided the or
Dedication waiver (http://creativecommons.or
unless otherwise stated.the process of gene transcription and is involved in the
mechanisms of deletional central (and presumably periph-
eral) tolerance. AIRE deficiency leads to the escape and
extra-thymic spreading of autoreactive T-cell clones: this
creates the basis for the onset of the autoimmune attack
against several tissue-specific self-antigens [1].
The clinical diagnosis of APS 1 is defined by the presence
of at least two components of the classic triad, which is
given by chronic mucocutaneous candidiasis (CMC),
chronic idiopathic hypoparathyroidism (HPT) and Addison
disease (AD). The disease generally begins in childhoodl Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
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age, followed by HPT and then by AD. Other endocrine
and non-endocrine components, such as hypergonadotro-
pic hypogonadism, hypothyroidism, type 1 diabetes, gastro-
intestinal dysfunction, autoimmune hepatitis, asplenia and
various ectodermal abnormalities (interstitial keratitis, alo-
pecia, vitiligo, nail dystrophy and dental enamel hypoplasia),
may occur with a different prevalence [2-5]. In addition to
ectodermal features, which are quite common features of
the disease, APS 1 patients may experience other types of
skin alterations. Indeed, in a restricted number of cases
a maculopapular, or morbilliform, or urticaria-like skin
rash, eventually accompanied by fever, splenomegaly
and arthralgia, has been reported [2,3,6-18]. When per-
formed, biopsy of the above lesions has revealed peri-
vascular, lymphoplasmacytic infiltrates in most of the
cases [3,11,12,18]. Whether skin involvement represents
the expression of a direct autoimmune attack, or an
unrelated event still remains to be defined.
Here we report on a challenging diagnosis of APS 1 in
a patient who presented at a very early age with a urti-
carial skin rash, with histopathological evidence of
vasculitis at skin biopsy, some years before the onset of
other classic components of the disease.
Case presentation
A 7-month-old female of non-consanguineous parents,
presented with a skin rash consisting of purple plaques
(maximum diameter 4 cm) with irregular and erythematous
margins, which were localized to the trunk and limbs. The
child also had mild splenomegaly and relapsing episodes of
joint pain with fever. Skin biopsy showed inflammatory
infiltrates within and around the walls of small vessels with
signs of endothelial damage in the form of endothelial
swelling, thus confirming a diagnosis of vasculitis. The child
underwent a diagnostic work-up, which showed increased
levels of C-reactive protein (27 mg/dl; n.v. <0.5), erythrocyte
sedimentation rate (66 mm/hour; n.v. <10) and immuno-
globulins (IgG 30.9 g/l; n.v. 1.7-10.7 and IgM 1.63 g/l; n.v.
0.3-1.3). C3 and C4 complement factors were within the
normal range (C3 1.13 g/l; n.v. 0.6-1.8 and C4 0.7 g/l; n.v.
0.07-0.7). Antibodies against common infectious agents
were negative. The percentage of double negative T lym-
phocytes (CD3 +CD4-CD8-), the lymphocyte response to
mitogens and lymphocyte sensitivity to FAS-induced apop-
tosis were all normal. Anti-nuclear (ANA), perinuclear (p-)
and cytoplasmic (c-) anti-neutrophil cytoplasmic (ANCA),
anti-thyroid, anti-double stranded (DS) DNA, anti-
phospolipids antibodies were all undetectable. Skin lesions
regressed spontaneously by the second year of life; bio-
chemical abnormalities also normalized during the follow-
up except levels of IgG and IgM which remained elevated.
The patient was then referred at the age of 5 years because
of recurrent oral candidiasis, alopecia of eyelashes andeyebrows, autoimmune thyroiditis, abdominal pain and
diarrhea. Despite a mild increase in serum TSH levels
(6 mIU/l), free-T4 (FT4) levels were normal, and the patient
did not require levothyroxine treatment [19].
Based on the persistence of candidiasis, cutaneous mani-
festations and autoimmune thyroiditis, direct sequencing
of the AIRE gene was performed, revealing 47C > T and
232 T >A variants in the exons 1 and 2, respectively, thus
confirming the diagnosis of APS 1. These variants were
inherited from the parents. Autoantibodies evaluation
revealed positive anti-thyroid, adrenal cortex, 17- and 21-
hydroxylase, gastric parietal cells, tryptophan hydroxylase,
side-chain cleavage, L-amino acid decarboxylase, and
steroid-producing cells antibodies (Table 1). Antibodies
against the IA-2 tyrosine phosphatase-like protein, insulin,
and glutamic acid decarboxylase were negative on several
controls. Anti-interferon antibodies were first evaluated
when she was 9 years-old, and were found to be positive.
During the follow-up the patient developed other signs
and symptoms of the disease. At the age of 9 years, she was
noted to have areas of vitiligo and signs of ectodermal dys-
trophy, such as dental enamel and nail dysplasia. HPT was
diagnosed at the age of 9 years on the basis of low calcium
(1.5 mmol/l) and parathyroid hormone levels (7 pg/ml, n.v.
10–65), and a treatment with calcitriol and calcium supple-
mentation was started. At the age of 11 years, increased
levels of ACTH (150 pg/ml; n.v. 10–130) and renin
(184 pg/ml; n.v. 1.8-3.3 pg/ml), with reduced cortisol peak
(108 ng/ml) after ACTH stimulation test, associated with
presence of anti-adrenal cortex, 17- and 21-hydroxylase
antibodies, led to the diagnosis of AD; therefore, gluco-
corticoid and mineralcorticoid replacement therapy were
started. Six months later she also started levothyroxine
treatment due to a further increase in TSH values (TSH
15 mU/ml), with reduced values of FT4 (0.6 ng/dl; n.v.
0.9-1.7). Patient’s pubertal development was normal and
she experienced menarche at the age of 10 years. How-
ever, at the age of 12 she had secondary amenorrhea
with increased gonadotropin levels (FSH 50 mUI/ml;
LH 35 mUI/ml). According to positivity of anti-steroid-
producing cells antibodies, a diagnosis of premature
ovarian failure due to autoimmune oophoritis was made,
therefore she started hormonal replacement therapy with
estrogens and progestins.
The clinical follow-up was also marked by an increase in
the extent of the alopecia, which affected over time a large
part of the scalp. Table 2 summarizes the clinical compo-
nents occurring over time in our patient, according to the
age of onset.
Discussion
We report on a child with APS 1 who presented with cu-
taneous vasculitis at a very early age, more than one year
before the onset of the typical features of the disease.
Table 1 First detection of specific autoantibodies compared to the age of onset of APS 1 components






Onset of APS 1
component (years)
Anti-thyroglobulin 5 5 Autoimmune thyroiditis 5
Anti-thyreoperoxidase 5 5 Autoimmune thyroiditis 5
Anti-parietal cells 7 7 Autoimmune gastritis -
Anti-adrenal cortex 7 7 Addison disease 11
Anti-21-hydroxylase 8 8 Addison disease 11
Anti-17alpha hydroxylase 8 8 Addison disease 11
Ovarian failure 12
Anti-P450 side chain cleavage 8 8 Addison disease 11
Ovarian failure 12
Anti-steroid-producing cells 8 8 Ovarian failure 12
Anti-tryptophan hydroxylase 9 10 Autoimmune hepatitis -
Autoimmune enteropathy 5
Anti-L-aminoacid decarboxylase 9 10 Vitiligo 9
Autoimmune hepatitis -
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scribed have been already included in a small case series
described by Capalbo et al. [20] and within an Italian
case series described by Mazza et al. [4]. However, these
two papers focused on the genetics and the phenotypic
heterogeneity of APS 1 patients originating from the
same geographic area (the former) and from several
Italian regions (the latter), and the clinical counterpart
of our patient was only briefly and partially discussed.
Aim of the current paper was to describe in detail this
patient with unusual presentation of APS 1, and to report
information of its clinical course. Indeed, in our opinion
such case raises interesting issues regarding the eventual
involvement of the skin in APS 1 and aware physicians to
consider the diagnosis of APS 1 when evaluating a patients
with unexplained cutaneous vasculitis.
APS 1 is characterized by high phenotypic heterogen-
eity, with a great variability in the number of the clinicalTable 2 Clinical course of APS 1 in our patient
APS 1 component Age of onset (years)
Cutaneous vasculitis 0.7
Mucocutaneous candidiasis 2





Chronic idiopathic hypoparathyroidism 9
Addison disease 11
Ovarian failure 12manifestations and the age at onset of the disease even
between patients with the same genotype [3-5]. Indeed,
the first clinical signs and/or symptoms may occur from
the first months of life up to adulthood [21], the earlier
presentation being generally associated with a more severe
phenotype and a higher number of clinical components
[1]. Although in its typical form APS 1 presents with at
least one of the classic triad, some patients suffer from
several minor manifestations of the disease for many years
before one of the first major components occurs [2].
When a rare or atypical component is the presenting
feature of the disease, the diagnosis of APS 1 can be
challenging and a considerable delay may occur between
the appearance of symptoms and the diagnosis [22].
Although skin rash represents a rare manifestation of
APS 1, to date a few patients with different forms of cuta-
neous eruptions have been described (Table 3) [2,3,6-18].
Only the minority of the cases reported were less than
1 year old [3,8,15].
Reports from Finnish population showed that 14% (13
out of 91 patients) of their cohort may exhibit periodic
morbilliform, maculopapular or urticarial skin rashes
with fever and/or arthralgia, appearing at age 0.7-31
years and lasting for 0.2-1.2 yr. Five out of these 13
patients, aged 0.7-1.2 years, showed high plasma IgG
levels. Moreover, four patients underwent skin biopsy,
revealing a lymphoplasmacytic vasculitis in two and no
specific pathology in the other cases. The same author
hypothesized an autoimmune pathogenesis of such
component [3].
In another large series of 41 APS 1 subjects from Italy,
only one patient was described as having cutaneous
vasculitis [2].
Table 3 Previous reports of skin involvement in APS 1 patients
Author and year of publication N. of cases Age at the onset of
skin lesions (yrs)
Aspect of skin lesions First typical component,
age at onset (yrs)
Biopsy
Case series
Craig JM et al. 1955 [7] 1/3 2.8 erythema marginatum/recurrent skin rash CMC, 3 increased melanin content
Betterle C et al. 1998 [2] 1/41 n.a. n.a. n.a. n.a.
Perheentupa J 2006 [3] 13/91 0.7–31 fleeting maculopapular, morbilliform, or urticarial rash n.a 2/4 biopsies revealed vasculitis
Trebušak Podkrajšek K et al. 2008 [6] 1/11 2 n.a. HPT, 7.5 n.a.
Posovszky C et al. 2012 [15] 2/13 1 n.a. CMC, 2.0 n.a
5 chronic recurrent urticaria CMC, 3.0
Case reports
Quinto MG et al. 1964 [8] 1 0.9 multiform erythema HPT + CMC, 4.0 n.a.
Stickler GB et al. 1965 [9] 1 7.6 evanescent trunkal macular rash HPT + CMC, 9.1 n.a.
Spörkmann K-H et al. 1990 [10] 1 1.2 multiform erythema HPT, 3.0 n.a.
Garty B 1998 [11] 1 22 erythema annulare centrifugum HPT, 5 lymphohistiocytic vasculitis
Füchtenbusch M et al. 2003 [12] 1 31 purpuric subepidermal nodules progressing
in deep cutaneous ulcers
HPT, 3.0 panniculitis and lymphocytic vasculitis
Kapelari K et al. 2004 [13] 1 16 photosensitive facial rash (diagnosis
of systemic lupus erythematosus)
n.a. n.a.
Hoorweg-Nijman G et al. 2008 [14] 1 1.2 n.a. HPT, 9.0 n.a.
Montin D et al. 2008 [16] 2 1.1 urticarial rash (vasculitic rash) CMC, 1.5 n.a.
7 urticarial rash CMC, 7.0
Rodríguez Sánchez De La
Blanca A et al. 2012 [18]
1 6 photosensitive rash HPT, 9.0 n.a.
O’ Gorman CS et al. 2013 [17] 1 1 intermittent urticarial rash HPT + CMC, 1 lymphocytic vasculitis
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countries (Serbia, Slovenia and Germany) the authors de-
scribed a Serbian APS 1 girl first presenting with recurrent
episodes of high fever, accompanied by cutaneous rash
and arthralgias at the age of two years, who was diagnosed
with systemic juvenile rheumatoid arthritis. This patient
also suffered from asthma-like dyspnea and developed the
first major APS 1 component (HPT) only when she was
7.5 years old [6].
Skin biopsy was performed in only a few cases, revealing
in most, but not all, evidence of an underlying vasculitis
[3,11,12,18]. For this reason, the prevalence of cutaneous
vasculitis in the context of APS 1 is unknown and it might
to be higher than that reported so far. As for our patient,
vasculitic skin rashes in patients with APS 1 have been
previously reported to be associated with other signs and/
or symptoms, such as therapy-resistant and/or recurrent
fever [6,7,9,10,13-16,18], polyarthritis [15], arthralgia
[3,6,12], hepato-splenomegaly [7,16] and photosensitivity
[13,17], as well as with laboratory and/or histological
abnormalities such as hypergammaglobulinemia [9,13,16],
elevated erythrocyte sedimentation rate [9,13], positive
rheumatoid factor [15], traces of cryoglobulinemia [2] and
panniculitis [12].
The clinical significance of cutaneous vasculitis in the
context of APS 1 is still debated. It may represent a rare,
unusual, early component of the disease or a clinical
manifestation secondarily related to the typical APS 1
components (i.e. autoimmune thyroid disease), which
are frequently associated with rheumatologic-like signs
and symptoms. Alternatively, it may be the expression of
an independent disease co-occuring with APS 1.
In this regard, taking into account that a complex clin-
ical picture including skin rash may continue for years
before some of the classic APS 1 components appear, it
is not surprising that some patients have been initially
suspected or diagnosed as having rheumatologic diseases
like juvenile rheumatoid arthritis and Wissler-Fanconi
syndrome [6,10] or other autoimmune disorders such as
autoimmune hepatitis [15]. In our patient, the presence
of early-onset cutaneous vasculitis, mild splenomegalia,
and serum hypergammaglobulinemia first suggested a
diagnosis of autoimmune lymphoproliferative syndrome
(ALPS). ALPS is a chronic, non-malignant lymphoprolif-
erative disorder due to mutations in the genes involved
in apoptosis. As for APS 1, it presents in the first years
of life (usually by 5 years of age) and its natural history
is characterized by the development of multiple auto-
immune manifestations [23]. However, in our case the
normal lymphocyte sensitivity to FAS-induced apoptosis
and the absence of double negative T cells (CD3 + CD4-
CD8-), which represent the immunological hallmark of
the disease, definitely ruled out a diagnosis of ALPS. The
diagnosis of APS 1 was suspected only when recurrentoral candidiasis and several autoimmune components
became evident, some years after the onset of cutaneous
vasculitis.
Early diagnosis of APS 1 and ongoing regular surveil-
lance, including periodic evaluation of hormonal and bio-
chemical parameters, are essential to allow the prevention
of severe and life-threatening events (i.e. hypocalcaemia,
adrenal crisis) [2]. Therefore, although clinical compo-
nents of APS 1 usually result from organ-specific auto-
immune targeting, our case suggests that APS 1 should be
also suspected in those cases presenting with immune-
mediated non-organ-specific diseases, such as cutaneous
vasculitis.
Recently, neutralizing autoantibodies against type 1 in-
terferons (IFN) (IFN-α and IFN-ω) have been found to
strictly correlate with AIRE deficiency, regardless of the
genotype, thus leading to consider these autoantibodies as
a precocious diagnostic tool for APS 1, even in the ab-
sence of the typical clinical picture or organ-specific auto-
antibodies [24,25]. However, it must be considered that
molecular analysis, despite more expensive than autoanti-
body assay, may be more easily accessible for many labora-
tories. In our case, assay for anti-IFN antibodies was not
available at the onset of the disease in our patient, but the
above antibodies were found to be positive at the age of
9 years. Therefore, we can only speculate that their posi-
tivity could have been useful for an earlier diagnosis.
In addition, our case confirms the importance of the
surveillance in searching for other sentinel autoantibodies,
mainly those against the adrenal cortex and the related
antigen targets, which show high predictive value for the
occurrence of the related clinical component [26,27].
Conclusions
In conclusion, although causal relationship between APS 1
and skin rashes or cutaneous vasculitis is still unclear, there
is evidence pointing toward a close link between these
conditions. Based on this hypothesis, our case provides
further evidence that several minor or rare autoimmune
or immune-mediated organ- and non-organ-specific dis-
eases, such as cutaneous vasculitis, may dominate the initial
clinical picture of APS 1, even for years before the develop-
ment of the classic components of the disease. Therefore,
although the diagnostic criteria of APS 1 remain valid, an
atypical phenotype of APS 1 should be suspected in the
presence of an early non-specific immune-mediated mani-
festation. Given the high specificity for APS 1 of anti-IFN
autoantibodies, their evaluation may be a simple diagnostic
tool for an early diagnosis. Finally, a regular check for hor-
monal, biochemical abnormalities, and organ-specific anti-
bodies should be performed during follow-up, in order to
recognize immune-mediated organs damage at an early
stage, thus allowing to prevent potentially life-threatening
events, such as hypocalcemia and adrenal failure.
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